Ontogen Medtech Awarded $258k Section I SBIR Grant From The NIH To Develop Revolutionary Pulmonary Embolism Catheter

Ontogen Medtech, a Chicago-based medical gadget design and improvement companies firm, has been awarded a $258,793 Section I Small Enterprise Innovation Analysis (SBIR) grant from the Nationwide Coronary heart, Lung, and Blood Institute (NHLBI) of the Nationwide Institute of Well being (NIH) to develop an modern catheter gadget to enhance the therapy of pulmonary embolism.

Ontogen Medtech is collaborating with Dr. Jonathan Paul and Dr. Osman Ahmed, founders of Move Medical, to optimize the design and improvement of the gadget with the purpose of bettering general affected person outcomes and doctor expertise. Dr. Paul and Dr. Ahmed follow interventional medication on the College of Chicago Medical Middle.

“We’re thrilled to be working hand-in-hand with two unbelievable physicians who’re capable of determine such a crucial medical want and collaborate successfully on product design ideas,” mentioned Tyler Panian, Principal and Co-Founding father of Ontogen Medtech. “This grant award validates that the NIH additionally sees a possibility for pulmonary embolism therapy strategies and strategies to be modernized and improved.”

Pulmonary embolism (PE) is a life-threatening medical situation whereby blood clots accumulate within the lungs.  Pulmonary embolism represents a number one reason for morbidity in the US, with as many as 900,000 circumstances per yr within the U.S. alone. One in 4 sufferers with PE will die immediately with out warning, and PE is the third most typical reason for cardiovascular loss of life. As well as, blood clots signify a big burden on the financial system, with healthcare prices accounting for as much as $10 billion {dollars} yearly. Catheter-directed thrombolysis (CDT) is a method of treating the embolism by infusing remedy instantly into the pulmonary artery to interrupt up the clots.

“Catheter-directed thrombolysis is an efficient and life-saving technique of treating pulmonary embolism, however it presently requires some guess work and with it come dangers of bleeding issues. We’re desperate to work with the Ontogen crew to eradicate this guess work and make the process safer for sufferers and extra streamlined for physicians,” mentioned Dr. Jonathan Paul.